Trial · NCT05789303
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303, Phase 2, Recruiting, University of Chicago
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma. Trials, record NCT05789303. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05789303
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- NCT number
- NCT05789303
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 83 participants, estimated
- Lead sponsor
- University of Chicago
- Conditions
- Multiple Myeloma, Relapse Multiple Myeloma
- Interventions
- Belantamab mafodotin, Carfilzomib, Pomalidomide, Dexamethasone
- First posted
- 2023-03-29
- Last updated
- 2026-09-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort) | 6-24 months | No prior CAR T-cell therapy cohort: Rate of very good partial response (VGPR) or better after 6 cycles according to the 2016 International Myeloma Working Group (IMWG) Response Criteria by Independent Review Committee (IRC). |
| Primary | Rate of Overall Response (Prior CAR T-Cell Therapy Cohort) | 6-24 months | Prior CAR T-cell therapy cohort: Rate of overall response (ORR) as determined by investigator assessment. |
| Secondary | Overall Response Rate | 6-24 months | Overall response rate as determined by the 2016 International Myeloma Working Group (IMWG) Response Criteria by Independent Review Committee (IRC) and investigator assessment. |
| Secondary | Minimal Residual Disease Negativity Rate | 6-24 months | Minimal Residual Disease (MRD) negativity rate as assessed by next generation sequencing (limit of detection \< 10-5). |
| Secondary | Progression-Free Survival | 6-24 months | Progression-free survival of participants as determined by investigator assessment. |
| Secondary | Overall Survival Among Participants | 6-24 months | Overall survival of participants as determined by investigator assessment. |
| Secondary | Frequency and Severity of Adverse Events (AEs)/ Serious Adverse Events | 6-24 months | Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by the Common Terminology Criteria for Adverse Events v5. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05789303
GET https://conductscience.org/api/trials/v1/NCT05789303/registered